[1]田瑞華,鄭良楷,孔令員,等.TET2蛋白在不同分子亞型乳腺癌中的表達及意義[J].福建醫(yī)藥雜志,2017,39(3):89-91.
　TIAN Ruihua,ZHENG Liangkai,Kong Lingyuan,et al.Expression and significance of TET2 in different molecular subtypes of breast cancer[J].FUJIAN MEDICAL JOURNAL,2017,39(3):89-91.
點擊復制

TET2蛋白在不同分子亞型乳腺癌中的表達及意義

分享到：

《福建醫(yī)藥雜志》[ISSN:1002-2600/CN:35-1071/R]

Title:: Expression and significance of TET2 in different molecular subtypes of breast cancer

Author(s):: TIAN Ruihua; ZHENG Liangkai; Kong Lingyuan; YANG Yibin; HUANG Zongyong; ZHOU Qiaorong; WANG Liping; ZHANG Aige

Keywords:: breast cancer; TET2; molecular subtype; clinical stages; prognostic biological marker

摘要:: 目的探討TET2蛋白(ten-eleventranslocation2)在不同分子亞型乳腺癌組織中的表達特點及與乳腺癌各臨床因素之間的關(guān)系.方法免疫組化檢測155例乳腺癌中TET2、ER、PR、Ki67和HER2蛋白的表達水平,FISH技術(shù)檢測HER2基因擴增情況,結(jié)合患者相關(guān)資料進行分析.結(jié)果TET2蛋白在LuminalB(HER2+)型乳腺癌組織中的表達水平明顯下調(diào)(P<0.001),在HER2陽性的乳腺癌組織中也發(fā)現(xiàn)TET2表達水平下調(diào)(P<0.001),并且TET2表達水平還受到腫瘤大小和淋巴結(jié)轉(zhuǎn)移等因素影響(P<0.001).結(jié)論TET2蛋白在不同分子亞型乳腺癌組織中的表達差異有統(tǒng)計學意義,并且與乳腺癌多項臨床特征有關(guān),可能有助于判斷乳腺癌的預(yù)后.

Abstract:: Objective To investigate the expression of TET2(ten-eleven translocation 2)in breast cancer tissues of different subtypes and the correlation between TET2 expression and clinic features of breast cancer.Methods The expression of TET2,ER,PR,Ki67 and HER2 was detected by streptavidin-peroxidase(SP),the expression of HER2 was detected by FISH in 155 cases of breast cancer,and the related data were combined with to analyze.Results The expression of TET2 was significantly decreased in Luminal B HER2 positive breast cancer tissues compared to that in others(P<0.001).TET2 expression was also significantly decreased in breast cancer with higher expression of HER2(P<0.001),and was affected by tumor size,and lymph node metastasis (P<0.001).Conclusion The expression of TET2 shows significant difference among different molecular subtypes of breast cancer.It is also related to the clinical features of breast cancer,which indicates that TET2 may be a prognostic biological marker in breast cancer.

[1]韓蕾林志武陳曉耕.早期乳腺癌前哨淋巴結(jié)活檢術(shù)125例臨床分析[J].福建醫(yī)藥雜志,2017,39(5):52.
[2]王瑞娟肖雪明曾煥紅林強.乳腺癌患者外周血循環(huán)腫瘤細胞檢測的臨床價值[J].福建醫(yī)藥雜志,2020,42(05):42.
[3]王一名,劉蘇燕,譚嬌麗,等.基于網(wǎng)絡(luò)藥理學探討復方斑蝥膠囊調(diào)控乳腺癌鐵死亡的機制研究[J].福建醫(yī)藥雜志,2024,46(01):106.[doi:10.20148/j.fmj.2024.01.030]
　WANG Yiming,LIU Suyan,TAN Jiaoli,et al.Research on the mechanism of compound mylabris capsules regulating ferroptosis in breast cancer based on network pharmacology and molecular docking[J].FUJIAN MEDICAL JOURNAL,2024,46(3):106.[doi:10.20148/j.fmj.2024.01.030]
[4]黃蓓蕾,王月桂,陳紅,等.PR基因表達聯(lián)合超聲影像構(gòu)建HER2陰性乳腺癌腋窩淋巴結(jié)轉(zhuǎn)移預(yù)測模型及應(yīng)用[J].福建醫(yī)藥雜志,2024,46(08):1.[doi:10.20148/j.fmj.2024.08.001]
　HUANG Beilei,WANG Yuegui,CHEN Hong,et al.Prediction model of axillary lymph node metastasis in HER2 negative breast cancer by PR gene expression combined with ultrasound image and its application[J].FUJIAN MEDICAL JOURNAL,2024,46(3):1.[doi:10.20148/j.fmj.2024.08.001]

更新日期/Last Update: 1900-01-01